We bring you our round-up of the latest legal and commercial issues for life sciences businesses.
In this issue we discuss the new MHRA guidance on the continued recognition of EU/EEA batch testing, plus we consider the contractual difficulties faced by life sciences companies in circumstances where demand for products exceeds capacity for supply.
We also look at the responses recently issued by the European Data Protection Board to questions raised by the European Commission clarifying the application of the GDPR in respect of processing personal data for health-related research.
Finally, the latest entry to our Life Sciences Legal A to Z explores the boundaries of “quality of confidence” and how this has particular relevance for businesses operating in the life sciences sector where protecting confidential information is paramount.
A link to the web version of this email update is available here. If you would like to receive these updates via email, please subscribe.
Charlotte Tillett
Beverley Flynn